跳轉至內容
Merck
HomeSmall Molecules Analysis & QCDrospirenone Assay: USP Monograph

Drospirenone Assay: USP Monograph

Drospirenone is a progestin medication that is used in birth control pills to prevent pregnancy and in menopausal hormone therapy. The Purospher® STAR RP-18e Hibar® HPLC column, 250 x 4.6 mm, 3 µm is used to demonstrate the assay of drospirenone following the USP monograph.1

Section Overview

Related Products
Loading
Chemical structure of drospirenone, a synthetic progestin, illustrated with multiple carbon rings, hydroxyl (–OH) and carbonyl (–C=O) groups, along with hydrogen atoms.

Figure 1.Chemical structure of Drospirenone.


Experimental Conditions

Standard Preparation

  • Add 25 mL of acetonitrile gradient grade and 25 mL of water into a graduated cylinder. Mix well - this is the acetonitrile:water (1:1) diluent.
  • Weigh ~25 mg of drospirenone CRM into a 5 mL volumetric flask.
  • Add ~4 mL of diluent to it and sonicate for 5 min.
  • Top-up to mark with diluent and mix well. This is the drospirenone stock standard.
  • Dilute to 0.3, 0.4, 0.5. 0.6, 0.7, 0.8 and 0.9 mg/mL with diluent.

Standard solution for relative standard deviation and tailing factor test: 0.6 mg/mL drospirenone in diluent

Standard concentrations for linearity, LOD and LOQ tests: 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 mg/mL in diluent

HPLC Method

The used HPLC conditions are shown in Table 1.

Table 1.HPLC conditions for drospirenone assay

Results and Discussion

System Suitability

Acceptance Criteria for Standard Solution:

  1. Tailing factor: 0.8 to 1.5
  2. Relative Standard Deviation: NMT 2.0%

The peak tailing factor is 1.10 (Table 2) and the % RSD of drospirenone is 0.2% (Table 3); both criteria are within the specifications defined in the monograph.

HPLC-UV assay of drospirenone 0.6 mg/mL standard solution

Figure 1.Drospirenone 0.6 mg/mL standard solution.

Table 2.Tailing factor of drospirenone, standard solution (average of 5 replicates)
Table 3.Repeatability of drospirenone, standard solution

Linearity, Limit of Detection (LOD) and Limit of Quantitation (LOQ)

The Limit of Detection (LOD) for drospirenone is 0.017 mg/mL and the Limit of Quantification (LOQ) is 0.052 mg/mL. The range from 0.3 to 0.9 mg/mL is linear with the R2 as 0.9995 (Table 4).

Table 4.Linearity, LOD and LOQ of drospirenone
A linearity curve graph showing the relationship between peak area and concentration of Drospirenone reference standard (RS) from 0.3 to 0.9 mg/mL. The x-axis represents concentration in mg/mL, while the y-axis represents peak area. Data points are indicated by blue dots, and a dotted line illustrates the linear regression with the equation (y = 150.33x - 0.8243) and an (R^2) value of 0.9995.

Figure 2.Linearity curve from 0.3 to 0.9 mg/mL of drospirenone.

The Purospher® STAR RP-18e Hibar® RT column is able to comply with the system suitability criteria indicated in the USP monograph for drospirenone using the described method. This column is therefore suitable for the determination following the USP monograph.

Pharma QC and Applications

References

1.
United States Pharmacopeia (2022). USP Monographs, Drospirenone. USP-NF. . https://doi.org/10.31003/USPNF_M28560_04_01
Related Articles
Related Product Categories
登入以繼續

若要繼續閱讀，請登入或建立帳戶。

還沒有帳戶？